3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.

3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.

The CIR “Credit Impôt Recherche” or French Research Tax Credit is a corporate tax relief measure that allows French companies to declare innovative research costs and obtain a significant reduction on their tax bill.

This renewal allows 3P’s French customers the opportunity to receive an important percentage of their R&D costs in tax credits. Therefore, 3P Biopharmaceuticals continues to bring added-value to their French clients thanks to this opportunity to increase the quality, safety and efficacy of their biologic drugs.

3P Biopharmaceuticals already counts with a strong French client portfolio at different stages of their biologics development who have embraced this interesting incentive over the last years.

3P Biopharmaceuticals successfully extends its French CIR certificate for 2020-2024.

As 3P Biopharmaceuticals CEO Dámaso Molero explains: “It is wonderful news to renew CIR certificate for another four years to confirm 3P Biopharmaceuticals, once again, as a valuable and competitive CDMO partner for French biotech and pharma companies interested in developing biologics.

3P Biopharmaceuticals once again demonstrates its capacity to carry out processes development and manufacturing of molecules developed within diverse therapeutic applications. At the same time, 3P Biopharmaceuticals consolidates a competitive position among the most esteemed CDMOs in Europe.

Our dedicated team of specialists will be happy to discuss any of your CDMO needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué.

3P Biopharmaceuticals, a Navarre company founded in 2007, met with 370 employees in an exciting and joyful event looking back over its 15 years of trajectory.
Read more

3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.

3P Biopharmaceuticals has completed the manufacture of BSG005 biomass planned for its client Biosergen. The client also recently announced Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus.
Read more

Regional Minister Irujo presents the Navarra Health Cluster

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.